Safety of topical calcineurin inhibitors in the treatment of vitiligo in children

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045920

Enrollment

Unknown

Registered

2021-04-28

Start date

2021-07-12

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged less than 18 years; 2. Long term continuous use of 0.03% tacrolimus (>6 months); 3. In the past two years, there was no use of other external drugs or oral glucocorticoids in the treatment of vitiligo; 4. The guardian fully understood the possible benefits and risks of long-term medication, agreed to collect blood and urine samples and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. With a history of spontaneous re-pigmentation; 2. With other autoimmune diseases, or another long-term medication history.

Design outcomes

Primary

Measure	Time frame
Metabolic markers;	—

Countries

China

Contacts

Public ContactXu Ai’e

The Third Hospital of Hangzhou

xuaiehz@hotmail.com+86 15967136252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026